<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02195609</url>
  </required_header>
  <id_info>
    <org_study_id>IP-2013-01</org_study_id>
    <nct_id>NCT02195609</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of Omega-3 vs Soy Isoflavones in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms</brief_title>
  <acronym>OMEGASI</acronym>
  <official_title>Randomized Open Label Study to Evaluate the Effect of (Omega-3) EPA + Docosahexaenoic Acid (DHA) vs Soy Isoflavones in 100 Postmenopausal Women Between 45-65 Years With Moderate to Severe Vasomotor Symptoms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aiming to evaluate changes in vasomotor symptoms in postmenopausal women
      treated for 4 months with Omega-3 vs Soy Isoflavones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-inferiority study of Omega 3 versus Soy Isoflavones, being each patient its own
      control from the baseline.

      In order to determine the difference observed in the evolution of intensity, frequency and
      the total number of hot flashes in 4 months in patients treated with Omega-3 vs Soy
      Isoflavones, is planned to include at least 100 patients, 50 per treatment arm.

      It si estimated a standar deviation of 0.5%, and a 10% lost follow-up rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the changes in vasomotor symptoms.</measure>
    <time_frame>0 to 4 months</time_frame>
    <description>To evaluate the changes in vasomotor symptoms in postmenopausal women measured by a hot flushes self-completed diary .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>0 and 4 months</time_frame>
    <description>serum cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with treatment</measure>
    <time_frame>at month 1 and 4</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood status</measure>
    <time_frame>0, 1 and 4 months</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health status</measure>
    <time_frame>months 0, 1 and 4</time_frame>
    <description>General health status by Short-Form 36 (SF-36) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating memory status</measure>
    <time_frame>at 0, 1 and 4 months</time_frame>
    <description>Alteration of the memory test (T@M)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>0 amd 4 months</time_frame>
    <description>serum triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>0, 1 and 4 months</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>0, 1 and 4 months</time_frame>
    <description>Body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>0, 1 and 4 months</time_frame>
    <description>abdominal circumference</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Menopause</condition>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>600 mg (EPA, DHA and Omega-3) twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy Isoflavones</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>54.4mg oral twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <description>600 mg oral twice a day</description>
    <arm_group_label>Omega-3</arm_group_label>
    <other_name>Om3gafort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy Isoflavones</intervention_name>
    <description>54.4 mg oral twice a day</description>
    <arm_group_label>Soy Isoflavones</arm_group_label>
    <other_name>Flavia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory and can complete all study procedures, which are able to read, understand
             and sign an informed consent and willing to come to the center for study visits.

          -  Postmenopausal (≥ 1 year of amenorrhea) or 6 months or more of amenorrhea with
             follicle stimulating hormone (FSH) ≥ 40 IU / L.

          -  BMI ≥ 18 kg/m2 and ≤ 30 kg/m2

          -  Flushing of moderate to severe intensity.

        Exclusion Criteria:

          -  Women with surgical menopause.

          -  Treatment with hormone replacement therapy (HRT) in the 3 months prior to inclusion

          -  Uterine bleeding after menopause with undetermined cause in the 12 months prior to
             screening.

          -  Presence or history of malignancy in the past 5 years.

          -  Malabsorption syndrome.

          -  Hype or uncontrolled hypothyroidism.

          -  Dyslipidemia (LDL-cholesterol&gt; 189 mg / dl or medical criteria) requiring an specific
             treatment of proven effectiveness.

          -  Chronic renal disease.

          -  Uncontrolled or untreated hypertension.

          -  Treatment with isoflavones, tibolone, Selective Estrogen Receptors Moderators (SERM´s)
             in the past 3 months prior to the testing selection period.

          -  Hormonal treatment with androgens, estrogens, progestins, alone or combined oral,
             transdermal, vaginal (including promestriene) or implant, in the last 3 months prior
             to testing selection period.

          -  Patients who receive or require treatment with antidepressants or anticonvulsants

          -  Patients with mental illness.

          -  History of noncompliance with taking medication.

          -  Suspected or abuse of alcohol or other drugs during the 12 months preceding the
             selection.

          -  Use of any experimental drug or device within 30 days prior to the selection.

          -  Any other condition or finding that a judgment of the investigator may jeopardise the
             tral conduct according to the protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Palacios, MD</last_name>
    <role>Study Director</role>
    <affiliation>President of the European Foundation Woman and Health,Past President and Honorary Member of the Spanish Menopause Society, President of the Council of Affiliated Menopause Societies (CAMS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vasomotor Symptoms Associated With Menopause</keyword>
  <keyword>Menopause</keyword>
  <keyword>Hot Flashes</keyword>
  <keyword>Postmenopausal Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

